Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
August 02, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
June 22, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
June 14, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced leader sponsorship of...
Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy
June 13, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 13, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the publication of...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy
June 05, 2023 07:00 ET
|
Avadel Pharmaceuticals plc
-LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy -Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major contribution to patient care...
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...